Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats

Journal of Feline Medicine and Surgery

Volumn 10, Issue 5, 2008, Pages 488-494

  Marshall, Rhett D ^a,b   Rand, Jacquie S ^a   Morton, John M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Cat Clinic   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD; CAT; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; RANDOMIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; CATS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; RANDOM ALLOCATION; TIME FACTORS;

EID: 51349169730     PISSN: 1098612X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfms.2008.05.002     Document Type: Article

References (20)

1. Appleton D.J., Rand J.S., Sunvold G.D., and Priest J. Determination of reference values for glucose tolerance, insulin tolerance and insulin sensitivity tests in clinically normal cats. American Journal of Veterinary Research 62 (2001) 630-636
2. Bantle J.P., and Laine D.C. Day-to-day variation in glycaemic control in type I and type II diabetes mellitus. Diabetes Research 8 (1988) 147-149
3. Bantle J.P., Weber M.S., Rao S.M.S., Chattopadhyay M.K., and Robertson R.P. Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. Journal of the American Medical Association 263 (1990) 1802-1806
4. Casella S.J., Mongilio M.K., Plotnick L.P., Hesterberg M.P., and Long C.A. Accuracy and precision of low-dose insulin administration. Pediatrics 91 (1993) 1155-1157
5. Christopher M.M., and O'Neill S. Effect of specimen collection and storage on blood glucose and lactate concentration in healthy, hyperthyroid, and diabetic cats. Veterinary Clinical Pathology 29 (2000) 22-28
6. Fleeman L.M., and Rand J.S. Evaluation of day to day variability of serial blood glucose concentration curves. Journal of the American Veterinary Medical Association 3 (2003) 317-321
7. Fonseca V., Bell D.S., Berger S., Thomson S., and Mecca T.E. A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences 328 (2004) 274-280
8. Fulcher G.R., Gilbert R.E., and Yue D.K. Glargine is superior to NPH for improving glycated hemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal 35 (2005) 536-542
9. Klein O., Lynge J., Endahl L., Damholt B., Nosek L., and Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes, Obesity and Metabolism 9 (2007) 290-299
10. Link KRJ (2001) Feline Diabetes: Diagnostics and Experimental Modelling [doctoral thesis]. The University of Queensland, Brisbane.
11. Lutz T.A., and Rand J.S. Comparison of five commercial radioimmunoassay kits for the measurement of feline insulin. Research in Veterinary Science 55 (1993) 64-69
12. Marshall R.D., and Rand J.S. Treatment with insulin glargine results in higher remission rates than lente or protamine zinc insulins in newly diagnosed diabetic cats (abstract). Journal of Veterinary Internal Medicine 19 (2005) 425
13. Marshall R.D., Rand J.S., and Morton J.M. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. Journal of Veterinary Pharmacology and Therapeutics 31 (2008) 205-212
14. Martin G., and Rand J.S. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats. Findings during the first week and after 5 or 9 weeks of therapy. Journal of Feline Medicine and Surgery 3 (2001) 23-30
15. Moberg E., Kollind M., Lins P.E., and Adamson U. Day-to-day variation of insulin sensitivity in patients with type 1 diabetes: role of gender and menstrual cycle. Diabetic Medicine 12 (1995) 224-228
16. 125I-labeled insulin glargine in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23 (2000) 813-819
17. Rand J.S., and Marshall R.D. Feline diabetes mellitus. In: Mooney, and Peterson (Eds). BSAVA Manual of Canine and Feline Endocrinology (2004), British Small Animal Veterinary Association, Gloucester 129-141
18. Robertson R.P., Tanaka Y., Sacchi G., Tran P.O.T., Gleason C., and Poitout V. Glucose toxicity of the β-cell: cellular and molecular mechanisms. In: LeRoith, Olefsky, and Taylor (Eds). Diabetes Mellitus (2000), Lippincott Williams & Wilkins, New York 125-132
19. Rowland M., and Tozer T.N. In: Rowland, and Tozer (Eds). Clinical Pharmacokinetics: Concepts and Applications. 2nd edn (1989), Lea & Febiger, Philadelphia 459-471
20. Weaver K.E., Rozanski E.A., Mahony O.M., Chan D.L., and Freeman L.M. Use of glargine and lente insulins in cats with diabetes mellitus. Journal of Veterinary Internal Medicine 20 (2006) 234-238